Silence Therapeutics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Silence Therapeutics PLC
Public (LSESLN)
Number of employees

Silence Therapeutics (AIM:SLN[1]) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters at 1 Lyric Square, London.


The targeting, delivery and ongoing structural modification of sequences are the three platforms for Silence Therapeutics's RNAi therapeutic development. These three platforms are:

  • proprietary siRNA sequences complied using bioinformatics algorithms and scientific research conjugated with GalNac Technology
  • development of siRNA structural features

Silence Therapeutics develops these structural modifications using three exclusive licences from the University of Massachusetts Amherst.


In 2005, the company acquired Atugen AG based in Germany, changing the company name to Silence Therapeutics AG. More recently in January 2010, Silence Therapeutics merged with Intradigm Corporation, a privately held biotechnology company in the United States that developed systematic RNA interference.[2]


Silence Therapeutics has multiple partnerships with other pharmaceutical companies, such as AstraZeneca, Pfizer/Quark Pharma and Dainippon Sumitomo.[3]


  1. ^ "Google Finance Stock Exchange listing for Silence Therapeutics". Retrieved 2011-09-16.
  2. ^ "Stockopedia - Silence Therapeutics Company History". Stockopedia. Retrieved 2011-09-16. |first1= missing |last1= in Authors list (help)
  3. ^ "Silence Therapeutics Collaborative Partnerships". Silence Therapeutics. Retrieved 2011-09-26. |first1= missing |last1= in Authors list (help)

External links[edit]